BMS-1001
CAS No. 2113650-03-4
BMS-1001( BMS 1001 | BMS1001 )
Catalog No. M13359 CAS No. 2113650-03-4
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 201 | Get Quote |
|
| 10MG | 295 | Get Quote |
|
| 25MG | 500 | Get Quote |
|
| 50MG | 705 | Get Quote |
|
| 100MG | 981 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-1001
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
DescriptionA potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS 1001 | BMS1001
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2113650-03-4
-
Formula Weight631.122
-
Molecular FormulaC35H35ClN2O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867.
2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
-
Tislelizumab
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
-
BMS-202
BMS-202 is a small molecule inhibitor of the PD-1/PD-L1 interaction with IC50 of 18 nM in a homogenous time-resolved fluorescence binding assay.
-
IMMH 010 maleate
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
Cart
sales@molnova.com